| Literature DB >> 32476295 |
Minglu Liu1, Xiaolu Ma1, Fu Shen1, Yuwei Xia2, Yan Jia2, Jianping Lu1.
Abstract
At the time of diagnosis, approximately 15%-20% of patients with rectal cancer (RC) presented synchronous liver metastasis (SLM), which is the most common cause of death in patients with RC. Therefore, preoperative, noninvasive, and accurate prediction of SLM is crucial for personalized treatment strategies. Recently, radiomics has been considered as an advanced image analysis method to evaluate the neoplastic heterogeneity with respect to diagnosis of the tumor and prediction of prognosis. In this study, a total of 1409 radiomics features were extracted for each volume of interest (VOI) from high-resolution T2WI images of the primary RC. Subsequently, five optimal radiomics features were selected based on the training set using the least absolute shrinkage and selection operator (LASSO) method to construct the radiomics signature. In addition, radiomics signature combined with carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) was included in the multifactor logistic regression to construct the nomogram model. It showed an optimal predictive performance in the validation set as compared to that in the radiomics model. The favorable calibration of the radiomics nomogram showed a nonsignificant Hosmer-Lemeshow test statistic (P > .05). The decision curve analysis (DCA) showed that the radiomics nomogram is clinically superior to the radiomics model. Therefore, the nomogram amalgamating the radiomics signature and clinical risk factors serve as an effective quantitative approach to predict the SLM of primary RC.Entities:
Keywords: magnetic resonance imaging; radiomics; rectal cancer; synchronous liver metastasis
Mesh:
Year: 2020 PMID: 32476295 PMCID: PMC7367643 DOI: 10.1002/cam4.3185
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
FIGURE 1Example image for rectal cancer contouring. A, The outline of regions of interest on one slice of axial T2‐weighted MR image. B, Volume rendering
Patient demographics
| Variables | Total | Training data (70%) | Validation data (30%) | Statistic |
|
|---|---|---|---|---|---|
| n = 127 (%) | n = 88 (%) | n = 39 (%) | |||
| Gender | |||||
| Male | 90 (70.9) | 63 (71.6) | 27 (69.2) | 0.073 | .787 |
| Female | 37 (29.1) | 25 (28.4) | 12 (30.8) | ||
| Age (y) | |||||
| Mean ± SD | 57.0 ± 10.6 | 57.8 ± 10.2 | 55.3 ± 11.2 | ‐1.257 | .211 |
| Location | |||||
| Upper | 26 (20.5) | 17 (19.3) | 9 (23.1) | 0.273 | .872 |
| Middle | 82 (64.6) | 58 (65.9) | 24 (61.5) | ||
| Lower | 19 (14.9) | 13 (14.8) | 6 (15.4) | ||
| mr T stage | |||||
| T1‐2 | 43 (33.9) | 29 (33.0) | 14 (35.9) | 0.105 | .746 |
| T3‐4 | 84 (66.1) | 59 (67.0) | 25 (64.1) | ||
| mr N stage | |||||
| N0 | 85 (66.9) | 57 (64.8) | 28 (71.8) | 0.602 | .438 |
| N1‐2 | 42 (33.1) | 31 (35.2) | 11 (28.2) | ||
| MRF | |||||
| Negative | 103 (81.1) | 72 (81.8) | 31 (79.5) | 0.096 | .757 |
| Positive | 24 (18.9) | 16 (18.2) | 8 (20.5) | ||
| EMVI | |||||
| Negative | 85 (66.9) | 57 (64.8) | 28 (71.8) | 0.602 | .438 |
| Positive | 42 (33.1) | 31 (35.2) | 11 (28.2) | ||
| CEA | |||||
| Negative | 82 (64.6) | 58 (65.9) | 24 (61.5) | 0.226 | .635 |
| Positive | 45 (35.4) | 30 (34.1) | 15 (38.5) | ||
| CA19‐9 | |||||
| Negative | 101 (79.5) | 69 (78.4) | 32 (82.1) | 0.220 | .639 |
| Positive | 26 (20.5) | 19 (21.6) | 7 (17.9) | ||
χ 2 – value.
t – value.
FIGURE 2Radiomics features selected by least absolute shrinkage and selection operator (LASSO) algorithm. Lasso algorithm for feature selection. Five features were selected
Logistic regression analyses of predicting synchronous liver metastasis
| Variables | Univariate logistic regression | Multivariate logistic regression | ||
|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| |
| Gender (male/female) | 1.647 (0.589‐4.609) | .342 | NA | NA |
| Age (y) | 0.981 (0.936‐1.027) | .410 | NA | NA |
| Location (lower/middle/upper) | 0.749 (0.353‐1.588) | .451 | NA | NA |
| mr T stage (T1‐2/T3‐4) | 2.744 (0.833‐9.039) | .097 | NA | NA |
| mr N stage (N0/N1‐2) | 2.068 (0.927‐4.612) | .076 | NA | NA |
| MRF (negative/positive) | 2.100 (0.662‐6.663) | .208 | NA | NA |
| EMVI (negative/positive) | 2.474 (0.92‐6.665) | .073 | NA | NA |
| CEA (negative/positive) | 12.629 (3.964‐40.232) | <.0001 | 8.040 (2.043‐31.640) | .003 |
| CA19‐9 (negative/positive) | 10.000 (3.059‐32.687) | <.0001 | 4.560 (1.038‐20.041) | .045 |
| Radiomics signature | 54.776 (5.274‐568.922) | .0008 | 70.629 (3.969‐1256.803) | .004 |
Abbreviations: NA, not available; OR, odds ratio.
FIGURE 3Radiomics nomogram to detect synchronous liver metastasis (SLM). The radiomics nomogram was developed in the training set with radiomics signature and tumor markers. In the nomogram, first, a vertical line was drawn according to the value of radiomics signature to determine the corresponding value of points. Similarly, the points of tumor markers were determined. The total points were the sum of the two points above. Finally, a vertical line was made according to the value of the total points to determine the probability of SLM
FIGURE 4Calibration curve. Training set (A) and validation set (B)
Receiver operator characteristic analysis of the prediction model for the training and validation sets
| Training set | Validation set | |||
|---|---|---|---|---|
| Radiomics | Nomogram | Radiomics | Nomogram | |
| AUC | 0.836 | 0.918 | 0.866 | 0.944 |
| 95% CI | 0.706‐0.965 | 0.824‐1.000 | 0.770‐0.963 | 0.895‐0.993 |
| Sensitivity | 100.0% | 90.00% | 79.17% | 95.83% |
| Specificity | 75.00% | 78.57% | 93.65% | 88.89% |
| Accuracy | 81.58% | 81.58% | 89.66% | 90.80% |
| PLR | 4.000 | 4.200 | 12.469 | 8.625 |
| NLR | 0.000 | 0.127 | 0.222 | 0.047 |
| PPV | 0.588 | 0.600 | 0.826 | 0.767 |
| NPV | 1.000 | 0.956 | 0.922 | 0.982 |
|
| 0.170 | 0.044 | ||
Abbreviations: NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value.
Compared by DeLong test.
FIGURE 5Receiver operator characteristic (ROC) curves (validation set). The prediction performance of the ROC curves for radiomics signature and radiomics nomogram for the validation set
FIGURE 6Decision curve analysis of the prediction model. Y‐axis represents the net benefit, which is calculated by gaining true positives and deleting false positives. The X‐axis is the probability threshold. The decision curve shows that if the probability of synchronous liver metastasis (SLM) ranges from 30% to 100%, using the radiomics nomogram to predict SLM provides more net benefit